指南与共识支持与姑息治疗消化系统肿瘤

2022年国际临床实践指南:癌症患者静脉血栓栓塞症的治疗与预防,包括COVID-19患者

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
指南 / 共识 · Lancet Oncol · 2022-01-01

国际血栓与癌症倡议组织基于截至2022年1月1日的文献综述,制定2022年癌症相关血栓治疗与预防临床实践指南,并纳入COVID-19患者。指南给出1A或1B级推荐,涵盖低分子肝素、直接口服抗凝药用于初始与维持治疗、术后预防及胰腺癌门诊患者一级预防等。

要点

  • 低分子肝素用于癌症相关血栓的初始(前10天)和维持治疗(1A或1B级推荐)。
  • 无高胃肠道或泌尿出血风险、无强药物相互作用或胃肠道吸收障碍者,直接口服抗凝药用于初始和维持治疗(1A或1B级推荐)。
  • 癌症相关血栓治疗至少6个月,可用低分子肝素或直接口服抗凝药(1A或1B级推荐)。

核心结论

  • 指南针对癌症相关血栓的治疗与预防给出1A或1B级推荐,并包含COVID-19患者的指导。

研究设计与样本

  • 国际血栓与癌症倡议组织为独立学术专家工作组,旨在建立癌症相关血栓治疗与预防的全球共识。
  • 2022年指南基于截至2022年1月1日的文献综述制定。

主要发现

  • 低分子肝素用于癌症相关血栓的初始(前10天)治疗和维持治疗(1A或1B级推荐)。
  • 直接口服抗凝药用于无高胃肠道或泌尿出血风险、无强药物相互作用或胃肠道吸收障碍患者的初始和维持治疗(1A或1B级推荐)。
  • 低分子肝素或直接口服抗凝药治疗癌症相关血栓至少6个月(1A或1B级推荐)。
  • 非高出血风险患者接受腹部盆腔大手术后,用低分子肝素延长预防(4周)以预防术后静脉血栓栓塞(1A或1B级推荐)。
  • 局部晚期或转移性胰腺癌门诊患者接受抗癌治疗且出血风险低者,用低分子肝素或直接口服抗凝药(利伐沙班或阿哌沙班)进行静脉血栓栓塞一级预防(1A或1B级推荐)。

关键数值与推荐

  • 推荐等级为1A或1B级。
  • 低分子肝素初始治疗为前10天。
  • 癌症相关血栓抗凝治疗至少6个月。
  • 术后预防延长4周。
  • 胰腺癌门诊患者一级预防用药为利伐沙班或阿哌沙班。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1) low-molecular-weight heparins (LMWHs) for the initial (first 10 days) treatment and maintenance treatment of cancer-associated thrombosis; (2) direct oral anticoagulants for the initial treatment and maintenance treatment of cancer-associated thrombosis in patients who are not at high risk of gastrointestinal or genitourinary bleeding, in the absence of strong drug-drug interactions or of gastrointestinal absorption impairment; (3) LMWHs or direct oral anticoagulants for a minimum of 6 months to treat cancer-associated thrombosis; (4) extended prophylaxis (4 weeks) with LMWHs to prevent postoperative venous thromboembolism after major abdominopelvic surgery in patients not at high risk of bleeding; and (5) primary prophylaxis of venous thromboembolism with LMWHs or direct oral anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic pancreatic cancer who are treated with anticancer therapy and have a low risk of bleeding.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022. PMID: 35772465. doi:10.1016/S1470-2045(22)00160-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。